Walk in to a Sharp vaccination clinic to get your COVID-19 vaccine
Doctor's office
Enter your doctor's name to get office information.
Find labs in your network
Enter your primary care doctor's name to find labs in your network.
Find urgent care centers in your network
Enter your primary care doctor's name to find urgent care centers in your network.
Verify your medical group

Refer to your insurance card or call your insurance provider to determine your medical group.

You can also search for your primary care doctor to find the medical group you and your doctor belong to.

Driving Directions
Update Information
Forgot Password

Please enter your e-mail address.

Sharp Health News

Sharp participates in breast cancer study

July 17, 2017

Sharp participates in breast cancer study

A new clinical trial is investigating whether patients with ductal carcinoma in situ (DCIS) should undergo less aggressive treatment — findings that could affect the care of tens of thousands of women diagnosed each year with this non-invasive form of breast cancer.

The trial — available through Sharp HealthCare and about 100 other cancer centers in the United States — is the first study of its kind to compare treatments for DCIS, a grouping of abnormal cells inside the milk ducts of a breast.

The disease is often called stage 0 breast cancer because the cells have not spread beyond the milk ducts. In the U.S., more than 60,000 women are diagnosed each year with DCIS, accounting for about 1 in 5 breast cancers.

Women with DCIS typically undergo the same treatment offered to patients with invasive breast cancer — a lumpectomy to remove the abnormal tissue from the breast, followed by radiation. A mastectomy is sometimes recommended if the disease is widespread in the milk ducts, or patients can choose to have a mastectomy as a preventive measure.

Deciding which surgery, if any, to undergo can be difficult for women, says Dr. Christina Casteel, medical director for the Breast Health Center at Sharp Memorial Hospital. Surgery can also lead to side effects such as long-term pain, scarring, loss of feeling and negative body image.

“Studies suggest that only about 30 percent of DCIS cases will progress to invasive cancer, so it’s important for doctors to have more clarity about whether we are overtreating DCIS under current recommendations,” Dr. Casteel says. “This clinical trial will help us get closer to that answer.”

The trial — called Comparison of Operative to Monitoring and Endocrine Therapy, or COMET — will compare the standard approach of surgery and radiation to active surveillance, when a woman is watched closely over time to see if the DCIS progresses.

Based out of Duke University, the trial aims to recruit 900 women with low-risk DCIS — typically women older than 40, with low-grade DCIS, who have no personal history of breast cancer. Patients who qualify to participate will be randomly assigned to either the surveillance group or the group receiving standard treatments.

Women in the surveillance group will see their doctor regularly and will receive mammograms every six months. If a woman develops invasive cancer during the trial, she can move into the standard treatment group. In both groups, women can receive endocrine therapy — medicines that stop hormones from helping breast cancer cells grow.

All participants will be monitored for anxiety, depression and other health-related, quality-of-life measures up to two years following their diagnosis.

Sharp HealthCare will enroll qualified participants at its three hospital sites: Sharp Memorial Hospital, Sharp Grossmont Hospital and Sharp Chula Vista Medical Center. The study will last a minimum of five years. Patients in either group can leave the study at any time.

For the news media: To talk with Dr. Casteel about breast cancer research for an upcoming story, contact Erica Carlson, senior public relations specialist, at erica.carlson@sharp.com.

You might also like:

Choose the doctor who's right for you.

At Sharp, we make it easy to find an exceptional doctor — right where you live and work.

All Categories
Contact Sharp HealthCare
Call us


For medical or psychiatric emergencies, call 911 immediately.

Email us

Please do not use this form to convey personal or medical information.

How would you like to be contacted?
Date of birth

Find other numbers

View our phone directory

What's This?

These important numbers are located on your billing statement.

Find your Sharp Rees-Stealy account number

Find your SharpCare account number

Find your SharpCare account number
What's GDPR?

The General Data Protection Regulation (GDPR) governs the processing of personal information gathered from individuals while they are in the European Union (EU) and parts of the EEA (European Economic Area, which currently includes Iceland, Lichtenstein and Norway).

We are sorry, but we are unable to process your price estimate if you live or are travelling within the EU or affiliated nations.

What's This?

Many surgery and procedure names sound similar. If possible, please provide the current procedure terminology (CPT) code, which can be found on the order from your doctor.

If you cannot provide the CPT code, please contact your doctor's office for the CPT or a detailed description of services.